" /> Filgotinib - CISMeF





Preferred Label : Filgotinib;

NCIt definition : An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. As JAK1 mediates signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation and activation of certain immune cells. JAK1 plays a key role in the signaling and activity of many cytokines and growth factors and is often dysregulated in a variety of autoimmune and inflammatory diseases, as well as some malignancies.;

UNII : 3XVL385Q0M;

InChIKey : RIJLVEAXPNLDTC-UHFFFAOYSA-N;

CAS number : 1206161-97-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1206161-97-8 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : GLPG0634; GLPG 0634; GS-6034;

NCI Metathesaurus CUI : CL556330;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
10/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.